Perhaps the Co now needs to split into 3 elements
1. Midkine (retain $20M R&D benefit) Value (once commercial partner onboard) > $100M
2. Advandgen (Personal care products) Value > $100M imo
3. Pharmaceutical distribution Value > $500M (imo of course)
sp > $5 imo by eoy ( or perhaps eom (April))
Perhaps the Co now needs to split into 3 elements1. Midkine...
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable